



ក្រសួងសុខាភិបាល

MINISTRY OF HEALTH

គណៈកម្មាធិការជាតិក្រុមស៊ីលធីប័

សំរាប់ការស្រាវជ្រាវសុខភាពដែលទាក់ទងនឹងមនុស្ស

National Ethics Committee for Health Research



លេខ...០៧១...N.E.C.H.R

ព្រះរាជាណាចក្រកម្ពុជា  
KINGDOM OF CAMBODIA  
ជាតិ សាសនា ព្រះមហាក្សត្រ  
NATION RELIGION KING



រាជធានីភ្នំពេញ, ថ្ងៃទី២៨...ខែ០៣...ឆ្នាំ២០១៤...

**Dr. Leang Rithea**

**Project:** Monitoring and evaluation of the therapeutic efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated falciparum malaria in Western Cambodia, an area of artemisinin-resistant falciparum malaria. Version N° 1, dated 08 /02/2014

**Reference:** - Your letter on 06<sup>th</sup> March ,2014  
- Summary report of NECHR’s secretaries on 21<sup>st</sup> March, 2014

Dear Dr. Leang Rithea,

I am pleased to inform you that your clarification of your study protocol entitled “Monitoring and evaluation of the therapeutic efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated falciparum malaria in Western Cambodia, an area of artemisinin-resistant falciparum malaria. Version N° 1, dated 08 /02/2014” has been approved by National Ethic Committee for Health Research (NECHR). This approval is valid for twelve months after the approval date.

The Principal Investigator of the project shall submit following document to the committee’s secretariat at the National Institute of Public Health at #2 Kim Il Sung Blvd, Khan Tuol Kok, Phnom Penh. (Tel: 855-23-880345, Fax: 855-23-881949):

- Annual progress report
- Final scientific report
- Patient/participant feedback (if any)
- Analyzing serious adverse events report (if applicable)

The Principal Investigator should be aware that there might be site monitoring visits at any time from NECHR team during the project implementation and should provide full cooperation to the team.

Regards,

Chairman

**Prof. ENG HUOT**